ECM
CBIO

Element Capital Management’s Crescent Biopharma CBIO Stock Holding History

Element Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-498
Closed -$809K – 891
2018
Q1 		$809K Buy
+498
New +$1.04M 0.02% 229
2017
Q4 		– Sell
-299
Closed -$418K – 143
2017
Q3 		$418K Sell
299
-536
-64% -$629K 0.17% 26
2017
Q2 		$931K Buy
+835
New +$690K 0.19% 27

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Element Capital Management's CBIO Position: Q2 2018 in Review

Element Capital Management sold out of Crescent Biopharma (CBIO) in Q2 2018, closing a stake of 498 shares — an estimated $809K sold.

Element Capital Management first reported a position in CBIO in Q2 2017 and held it in 3 quarters. The position peaked at $931K in Q2 2017. 84 funds tracked by Wall St. Rank hold CBIO as of Q2 2018.

  • Element Capital Management reported no remaining Crescent Biopharma position as of Q2 2018 after selling out during the quarter.
  • Element Capital Management sold 498 Crescent Biopharma shares in Q2 2018, an estimated $809K.
  • Element Capital Management first reported a position in Crescent Biopharma in Q2 2017 and held it in 3 quarters.
  • Element Capital Management's Crescent Biopharma position peaked at $931K in Q2 2017.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2018.

Based on Element Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.